Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
09-11 April, 2025
Not Confirmed
Not Confirmed
26-29 March, 2025
Not Confirmed
Not Confirmed
27-29 March, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
09-11 April, 2025
Industry Trade Show
Not Confirmed
26-29 March, 2025
Industry Trade Show
Not Confirmed
27-29 March, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/molecular-glue-degraders-lilly-abbvie-sign-billion-dollar-deals-bms-leads-with-three-late-stage-drugs
21 Mar 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250321141701/en/Summit-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4
17 Mar 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250317175356/en/Robert-LaCaze-Innovative-Growth-Driver-in-Oncology-Joins-Summit-Therapeutics-as-Chief-Commercial-Officer
24 Feb 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250224344635/en/Summit-Therapeutics-Announces-Clinical-Trial-Collaboration-with-Pfizer-to-Evaluate-Ivonescimab-in-Combination-with-Pfizer-Antibody-Drug-Conjugates-ADCs#:~:text=(NASDAQ%3A%20SMMT)%20today%20announced,across%20multiple%20solid%20tumor%20settings.
24 Feb 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/akeso-highlights-collaboration-between-its-partner-summit-therapeutics-and-pfizer-to-explore-ivonescimab-in-combination-with-pfizers-adcs-302383996.html
24 Feb 2025
// BUSINESSWIRE
18 Feb 2025
// BUSINESSWIRE
ABOUT THIS PAGE